acyclovir

Summary

Summary: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Top Publications

  1. pmc Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2
    C Celum
    Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA
    N Engl J Med 362:427-39. 2010
  2. pmc Effect of herpes simplex suppression on incidence of HIV among women in Tanzania
    Deborah Watson-Jones
    London School of Hygiene and Tropical Medicine, London
    N Engl J Med 358:1560-71. 2008
  3. ncbi Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus
    Nicolas Nagot
    Centre Muraz, Bobo Dioulasso, Burkina Faso
    N Engl J Med 356:790-9. 2007
  4. pmc Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    J Infect Dis 198:1804-8. 2008
  5. ncbi Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability
    Claudia Giannavola
    Department of Pharmaceutical Sciences, University of Catania, I 95125 Catania, Italy
    Pharm Res 20:584-90. 2003
  6. ncbi Natural history of neonatal herpes simplex virus infections in the acyclovir era
    D W Kimberlin
    Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA
    Pediatrics 108:223-9. 2001
  7. ncbi Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial
    Philippe Mayaud
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    J Infect Dis 200:216-26. 2009
  8. ncbi Herpes simplex virus resistance to antiviral drugs
    Florence Morfin
    Laboratory of Virology of the Hospices Civils de Lyon, Domaine Rockefeller, 8 avenue Rockefeller, 69373 Cedex 08, Lyon, France
    J Clin Virol 26:29-37. 2003
  9. pmc Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy
    Teresa H Bacon
    GlaxoSmithKline Consumer Healthcare, Weybridge, Surrey KT15 0DE, United Kingdom
    Clin Microbiol Rev 16:114-28. 2003
  10. ncbi Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial
    Richard A Zuckerman
    Section of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    J Infect Dis 196:1500-8. 2007

Detail Information

Publications315 found, 100 shown here

  1. pmc Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2
    C Celum
    Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA
    N Engl J Med 362:427-39. 2010
    ..Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1...
  2. pmc Effect of herpes simplex suppression on incidence of HIV among women in Tanzania
    Deborah Watson-Jones
    London School of Hygiene and Tropical Medicine, London
    N Engl J Med 358:1560-71. 2008
    ..This study tested the hypothesis that HSV-2 suppressive therapy reduces the risk of HIV acquisition...
  3. ncbi Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus
    Nicolas Nagot
    Centre Muraz, Bobo Dioulasso, Burkina Faso
    N Engl J Med 356:790-9. 2007
    ..Epidemiologic data suggest that infection with herpes simplex virus type 2 (HSV-2) is associated with increased genital shedding of human immunodeficiency virus type 1 (HIV-1) RNA and HIV-1 transmissibility...
  4. pmc Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    J Infect Dis 198:1804-8. 2008
    ..001]), as was cervical HIV-1 level (-0.35 log10 copies/swab, a 55% decrease [P < .001]). Suppressive HSV-2 therapy has the potential to reduce HIV-1 infectiousness and slow HIV-1 disease progression...
  5. ncbi Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability
    Claudia Giannavola
    Department of Pharmaceutical Sciences, University of Catania, I 95125 Catania, Italy
    Pharm Res 20:584-90. 2003
    The evaluation of nanosphere colloidal suspensions containing acyclovir as potential ophthalmic drug delivery systems was carried out...
  6. ncbi Natural history of neonatal herpes simplex virus infections in the acyclovir era
    D W Kimberlin
    Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA
    Pediatrics 108:223-9. 2001
    ..The objective of this study was to provide an update of neonatal HSV disease to identify means by which future improvements in the management of HSV-infected neonates can be made...
  7. ncbi Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial
    Philippe Mayaud
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    J Infect Dis 200:216-26. 2009
    ..Little is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1)...
  8. ncbi Herpes simplex virus resistance to antiviral drugs
    Florence Morfin
    Laboratory of Virology of the Hospices Civils de Lyon, Domaine Rockefeller, 8 avenue Rockefeller, 69373 Cedex 08, Lyon, France
    J Clin Virol 26:29-37. 2003
    Herpes simplex virus (HSV) infections are efficiently treated with antiviral drugs such as acyclovir (ACV)...
  9. pmc Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy
    Teresa H Bacon
    GlaxoSmithKline Consumer Healthcare, Weybridge, Surrey KT15 0DE, United Kingdom
    Clin Microbiol Rev 16:114-28. 2003
    b>Acyclovir, penciclovir, and their prodrugs have been widely used during the past two decades for the treatment of herpesvirus infections. In spite of the distribution of over 2...
  10. ncbi Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial
    Richard A Zuckerman
    Section of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    J Infect Dis 196:1500-8. 2007
    ..We studied HIV-1 levels during HSV suppression in coinfected persons in a placebo-controlled crossover trial...
  11. pmc Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial
    Steven J Reynolds
    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Lancet Infect Dis 12:441-8. 2012
    ..We investigated the effect of daily suppressive aciclovir on HIV-1 disease progression in Rakai, Uganda...
  12. ncbi Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children
    Yi Wang
    State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
    J Clin Virol 52:107-12. 2011
    The occurrence of herpes simplex virus (HSV) with acyclovir (ACV) resistance is a cause for concern due to the frequent use of ACV for treatment, suppressive therapy, and prophylaxis of HSV infection...
  13. pmc High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial
    Kenneth Mugwanya
    Infectious Diseases Institute, Makerere University, Kampala, Uganda
    J Infect Dis 204:1912-7. 2011
    Standard-dose HSV-2 suppressive therapy (acyclovir 400 mg twice daily) reduces plasma HIV-1 levels by 0.25-0.50 log(10) copies/mL. It is not known if higher doses might further suppress HIV-1 levels.
  14. ncbi Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS)
    Deepa Patel
    TIFAC CORE IN NDDS, Pharmacy Department, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Vadodara, India
    Drug Dev Ind Pharm 33:1318-26. 2007
    b>Acyclovir is a potent anti-viral agent useful in the treatment of Herpes Simplex Virus (HSV) infections...
  15. pmc A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial
    Shevin T Jacob
    Department of Medicine, University of Washington, Seattle, WA, USA
    AIDS Behav 15:897-904. 2011
    ..who completed HPTN 039, a randomized, placebo-controlled trial of HSV-2 suppression with twice-daily acyclovir to reduce HIV-1 acquisition. Of the 3172 trial participants, 2003 (63%) completed the post-trial questionnaire...
  16. ncbi Risk of acute kidney injury from oral acyclovir: a population-based study
    Ngan N Lam
    Division of Nephrology, Western University, London, Ontario, Canada
    Am J Kidney Dis 61:723-9. 2013
    Intravenous acyclovir-induced acute kidney injury (AKI) from drug crystallization in the renal tubules is described in case reports, review articles, and drug prescribing manuals...
  17. pmc Oral acyclovir suppression and neurodevelopment after neonatal herpes
    David W Kimberlin
    Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA
    N Engl J Med 365:1284-92. 2011
    ..Poor neurodevelopmental outcomes and recurrences of cutaneous lesions remain unacceptably frequent among survivors of neonatal herpes simplex virus (HSV) disease...
  18. pmc Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial
    Clare Tanton
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    J Infect Dis 201:1285-97. 2010
    ..Herpes simplex virus (HSV) suppressive therapy reduces genital and plasma human immunodeficiency virus type 1 (HIV-1) RNA over periods up to 3 months, but the long-term effect is unknown...
  19. ncbi Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial
    Gabriela Paz-Bailey
    National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 200:1039-49. 2009
    It is uncertain whether episodic acyclovir will enhance ulcer healing if delivered at primary health care settings, because there is often a delay in treatment initiation.
  20. ncbi Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis
    Rui Duan
    Department of Virology, Erasmus Medical Centre, Rotterdam, The Netherlands
    J Infect Dis 198:659-63. 2008
    ..of isolates from 173 immunocompetent patients with herpetic keratitis (HK) who were infected with acyclovir (ACV)-resistant (ACV(R)) corneal herpes simplex virus (HSV)-1 was determined. Isolates from 11 (6...
  21. ncbi Neonatal herpes simplex virus infection
    Richard Whitley
    University of Alabama at Birmingham, Birmingham, Alabama 35233, USA
    Curr Opin Infect Dis 17:243-6. 2004
    ..This review considers recent advances that impact on disease management...
  22. pmc High-frequency phenotypic reversion and pathogenicity of an acyclovir-resistant herpes simplex virus mutant
    Anthony Griffiths
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Virol 77:2282-6. 2003
    ..a run of guanines in the herpes simplex virus gene encoding thymidine kinase (TK) was previously found in an acyclovir-resistant clinical isolate...
  23. ncbi Enhancement of the anti-herpetic effect of trichosanthin by acyclovir and interferon
    Y T Zheng
    Kunming Institute of Zoology, The Chinese Academy of Sciences, PR China
    FEBS Lett 496:139-42. 2001
    ..The ED(50) of TCS was reduced 125-fold by acyclovir at a concentration of 0.001 microg/ml, which was practically devoid of significant anti-viral activity...
  24. pmc Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence
    DEBORAH J DONNELL
    Department of Global Health, University of Washington, Seattle, USA
    AIDS Behav 17:632-9. 2013
    ..the Partners in Prevention HSV/HIV Transmission Study, a double-blind, placebo controlled trial of twice-daily acyclovir suppression of herpes simplex virus type 2 (HSV-2) in HIV-1 infected persons was used to compare changes between ..
  25. ncbi Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities
    Uta K Meyding-Lamadé
    Department of Neurology, INF 400 Kopfklinik, Heidelberg, Germany
    J Neurovirol 9:118-25. 2003
    ..This study aimed to evaluate a possible beneficial effect of a therapy of acyclovir and corticosteroids versus acyclovir only...
  26. ncbi Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals
    Monique van Velzen
    Department of Virology, Laboratory of Neuro Oncology and Clinical and Cancer Proteomics, Erasmus Medical Center, The Netherlands
    J Infect Dis 205:1539-43. 2012
    Specific mutations within the hypervariable herpes simplex virus (HSV) gene thymidine kinase (TK) gene lead to acyclovir (ACV) resistance...
  27. ncbi Three-dimensional analysis of combination effect of ellagitannins and acyclovir on herpes simplex virus types 1 and 2
    N Vilhelmova
    Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 G Bonchev Str, 1113 Sofia, Bulgaria
    Antiviral Res 89:174-81. 2011
    ..of three nonahydroxyterphenoyl-bearing C-glucosidic ellagitannins (castalagin, vescalagin and grandinin) with acyclovir (ACV) on the replication of type-1 and type-2 herpes simplex viruses in MDBK cells were tested by the focus-..
  28. ncbi Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study
    Elisabetta Miserocchi
    Department of Ophthalmology and Visual Sciences, San Raffaele Scientific Institute, Milan, Italy
    Am J Ophthalmol 144:547-51. 2007
    To compare the efficacy of one-year treatment with valacyclovir vs acyclovir in preventing recurrence of the herpes simplex virus (HSV) eye disease.
  29. ncbi Biotransformation of the antiviral drugs acyclovir and penciclovir in activated sludge treatment
    Carsten Prasse
    Federal Institute of Hydrology BfG, Koblenz, Germany
    Environ Sci Technol 45:2761-9. 2011
    The biotransformation of the two antiviral drugs, acyclovir (ACV) and penciclovir (PCV), was investigated in contact with activated sludge...
  30. pmc The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production
    Qiao Meng
    Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin Madison, Madison, WI 53706, USA
    J Virol 84:4534-42. 2010
    Ganciclovir (GCV) and acyclovir (ACV) are guanine nucleoside analogues that inhibit lytic herpesvirus replication...
  31. ncbi Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection
    F Jacquemard
    Service de Medecine Foetale, Institut de Puericulture de Paris, Paris, France
    BJOG 114:1113-21. 2007
    ..To report early experience with treatment of intrauterine cytomegalovirus (CMV) infection using maternal oral administration of valaciclovir (VACV)...
  32. pmc Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study
    Biswajit Mukherjee
    Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
    Int J Nanomedicine 2:213-25. 2007
    The present study was designed to develop and compare acyclovir containing nano-vesicular liposomes and niosomes based on cholesterol, soya L-alpha-lecithin and nonionic surfactant, span 20...
  33. ncbi Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2
    Christina Ludema
    Department of Epidemiology, University of North Carolina, Chapel Hill, USA
    AIDS 25:1265-9. 2011
    To summarize the randomized evidence regarding the association between acyclovir use and HIV-1 replication as measured by plasma HIV-1 RNA viral load among individuals coinfected with herpes simplex virus (HSV)-2.
  34. ncbi Regression of herpes viral infection symptoms using melatonin and SB-73: comparison with Acyclovir
    Odilon da Silva Nunes
    Universidade Federal de Sao Carlos, Departamento de Fisioterapia, Dr Nivaldo s laboratory, Rod Washington Luis, Sao Carlos, SP, Brazil
    J Pineal Res 44:373-8. 2008
    ..The usual drugs used for herpes are Vidarabine, Acyclovir, Penciclovir and Ganciclovir; they are associated with several complications...
  35. ncbi Acute retinal necrosis features, management, and outcomes
    Chun H Lau
    Department of Clinical Ophthalmology, Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom
    Ophthalmology 114:756-62. 2007
    ..To determine the viral diagnosis and factors affecting the visual outcome of eyes with acute retinal necrosis...
  36. pmc Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial
    Alison L Drake
    Department of Global Health, University of Washington, Seattle 98195 7236, USA
    J Infect Dis 205:366-75. 2012
    ..The effect of herpes simplex virus type 2 (HSV-2) suppression on human immunodeficiency virus type 1 (HIV-1) RNA in the context of prevention of mother-to-child transmission (PMTCT) interventions is unknown...
  37. ncbi Conjugation of squalene to acyclovir improves the affinity for biomembrane models
    Maria Grazia Sarpietro
    Dipartimento di Scienze Chimiche, Universita degli Studi di Catania, Viale Andrea Doria 6, 95125 Catania, Italy
    Int J Pharm 382:73-9. 2009
    Differential scanning calorimetry was used to study the interaction of acyclovir and its prodrug squalenoyl-acyclovir (obtained by conjugation of 1,1',2-tris-nor-squalene acid (squaleneCOOH) with acyclovir) with biomembrane models made ..
  38. ncbi The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics
    Lawrence Corey
    Department of Medicine, University of Washington Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Acquir Immune Defic Syndr 35:435-45. 2004
    ..Subclinical HSV reactivation elevates serum HIV-1 RNA levels, and daily therapy with acyclovir appears to reduce plasma HIV-1 RNA...
  39. pmc A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2
    Christophe Vanpouille
    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 201:635-43. 2010
    ..Therefore, suppression of one virus infection will affect the other. Acyclovir, a common antiherpetic drug, was shown to directly suppress both viruses in coinfected tissues...
  40. ncbi Impact of aciclovir on ulcer healing, lesional, genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi
    SAM PHIRI
    Lighthouse Centre, Kamuzu Central Hospital, Lilongwe, Malawi
    Sex Transm Infect 86:345-52. 2010
    ..By a randomised, double-blind, placebo-controlled trial of aciclovir 800 mg twice daily for 5 days added to the syndromic management of genital ulcer disease (GUD) to determine the impact on ulcer healing and HIV outcomes...
  41. pmc Acyclovir or Aβ42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells
    Walter J Lukiw
    LSU Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, 2020 Gravier Street, Suite 904, New Orleans, LA 70112 2272, USA
    Neuroreport 21:922-7. 2010
    ..Presence of the antiviral acyclovir or soluble Abeta42 peptide significantly attenuated these neuropathological responses...
  42. ncbi Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir
    Zeljka Pavelić
    Department of Pharmaceutics, Faculty of Pharmacy and Biochemistry, University of Zagreb, A Kovacica 1, POB 156, 10000 Zagreb, Croatia
    J Control Release 106:34-43. 2005
    Design of a liposome delivery system for vaginal administration of acyclovir, able to provide sustained release and improved bioavailability of the encapsulated drug for the local treatment of genital herpes was investigated...
  43. ncbi Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections
    D W Kimberlin
    Department of Pediatrics, University of Alabama at Birmingham, Alabama 35233, USA
    Pediatrics 108:230-8. 2001
    The objective of this investigation was to establish the safety of high-dose (HD) acyclovir for the treatment of neonatal herpes simplex virus (HSV) disease...
  44. ncbi Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial
    Mats Engstrom
    Department of Otorhinolaryngology and Head and Neck Surgery, Uppsala University Hospital, Uppsala, Sweden
    Lancet Neurol 7:993-1000. 2008
    ..The aim of this study was to compare the short-term and long-term effects of prednisolone and valaciclovir in the recovery of the affected facial nerve in a large number of patients...
  45. pmc HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men
    Richard A Zuckerman
    Section of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    AIDS 23:479-83. 2009
    ..Suppressive herpes simplex virus (HSV) therapy can decrease plasma, cervical, and rectal HIV-1 levels in HIV-1/HSV-2 co-infected persons. We evaluated the effect of HSV-2 suppression on seminal HIV-1 levels...
  46. pmc Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition
    Jia Zhu
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Nat Med 15:886-92. 2009
    ..The persistence and enrichment of HIV receptor-positive inflammatory cells in the genitalia help explain the inability of anti-HSV-2 therapy to reduce HIV acquisition...
  47. ncbi Comparative study of transfer factor and acyclovir in the treatment of herpes zoster
    S Estrada-Parra
    Department of Immunology, National School of Biological Sciences, National Polytechnic Institute, Prol Carpio y Plan de Ayala, Mexico, D F
    Int J Immunopharmacol 20:521-35. 1998
    ..Of all the antiviral agents employed, acyclovir has been the most successful in reducing post herpetic pain...
  48. ncbi Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis
    K A Thompson
    Infectious Diseases Unit, School of Medicine, Monash University, Victoria, Australia
    J Neurovirol 6:25-32. 2000
    ..After injection of HSV-1, rats were treated twice a day, either with vehicle (saline, 400 microl i.p.), with acyclovir (30 mg/kg i.p.), with dexamethasone (5 mg/kg i.p.), or with both acyclovir and dexamethasone...
  49. pmc Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring
    John A Moss
    Department of Chemistry, Oak Crest Institute of Science, Pasadena, California, USA
    Antimicrob Agents Chemother 56:875-82. 2012
    ..Incorporation of the antiretroviral tenofovir (TFV) along with the antiherpetic acyclovir (ACV) into combination intravaginal rings (IVRs) for sustained mucosal delivery of both compounds could lead to ..
  50. ncbi Increased acyclovir oral bioavailability via a bile acid conjugate
    Sanna Tolle-Sander
    Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21202, USA
    Mol Pharm 1:40-8. 2004
    The objective of this work was to design an acyclovir prodrug that would utilize the human apical sodium-dependent bile acid transporter (hASBT) and enhance acyclovir oral bioavailability...
  51. ncbi Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir
    M Fresta
    Department of Pharmaceutical Sciences, Viale Andrea Doria 6, I-95125 Catania, Italy
    J Pharm Sci 90:288-97. 2001
    b>Acyclovir-loaded polyethyl-2-cyanoacrylate (PECA) nanospheres were prepared by an emulsion polymerization process in the micellar phase and characterized...
  52. pmc Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment
    A Wald
    Department of Medicine, University of Washington, Seattle 98195, USA
    J Clin Invest 99:1092-7. 1997
    ..were obtained from 27 HSV-2 seropositive women; a subset of subjects obtained samples while receiving oral acyclovir 400 mg PO twice a day. HSV DNA was detected in genital swab specimens on 28% of 1,410 d compared with 8...
  53. ncbi Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome
    Mazyar Ziyaeyan
    Professor Alborzi Clinical Microbiology Research Center and Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
    Int J Dermatol 46:1263-6. 2007
    ..b>Acyclovir (ACV) is widely used for the treatment and prophylaxis of HSV infections...
  54. ncbi Acute retinal necrosis: a case series with clinical features and treatment outcomes
    Joanne L Sims
    Ocular Immunology Clinic, The Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia
    Clin Experiment Ophthalmol 37:473-7. 2009
    ..To determine clinical features, viral aetiology and treatment outcomes of eyes with acute retinal necrosis (ARN)...
  55. pmc Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study
    H B Hoh
    Bristol Eye Hospital
    Br J Ophthalmol 80:140-3. 1996
    AIMS: This study was designed to assess the relative efficacy of topical ganciclovir 0.15% gel and acyclovir 3% ointment in the treatment of herpes simplex dendritic keratitis...
  56. ncbi Preparation and in vitro evaluation of the antiviral activity of the Acyclovir complex of a beta-cyclodextrin/poly(amidoamine) copolymer
    Marco Bencini
    Dipartimento di Chimica Organica e Industriale, and Centro Interdisciplinare Materiali e Interfacce Nanostrutturati CIMAINA Università di Milano, via Venezian 21, 20133 Milano, Italy
    J Control Release 126:17-25. 2008
    ..The complexing capacity of beta-CD/PAA was determined using an antiviral drug, Acyclovir, as a model of poorly water-soluble drug. Complex formation was confirmed by means of DSC and FTIR analyses...
  57. ncbi Synthesis and biological activity of strongly fluorescent tricyclic analogues of acyclovir and ganciclovir
    Tomasz Goslinski
    Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12 14, 61 704 Poznan, Poland
    J Med Chem 45:5052-7. 2002
    In search of strongly fluorescent tricyclic analogues of acyclovir (ACV, 1) and ganciclovir (GCV, 2), derivatives of the 3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purine system, several 6-[4-(acyloxy)phenyl], 6-[4-(acylamino)phenyl], and 6-[4-(..
  58. ncbi [Encephalopathy and acute renal failure during acyclovir treatment]
    A Delluc
    Service de Neurologie, CHU de la Cavale Blanche, Brest, France
    Rev Neurol (Paris) 160:704-6. 2004
    Adverse neurological and renal effects can occur in patients taking acyclovir. Neurotoxicity of acyclovir results from an accumulation of the antiviral and its metabolites in the bloodstream...
  59. ncbi Enhanced antiviral activity of Acyclovir loaded into beta-cyclodextrin-poly(4-acryloylmorpholine) conjugate nanoparticles
    Roberta Cavalli
    Dipartimento di Scienza e Tecnologia del Farmaco, Universita degli Studi di Torino, via P Giuria 9, 10125 Torino, Italy
    J Control Release 137:116-22. 2009
    ..b>Acyclovir-loaded nanoparticles were prepared from inclusion complexes of Acyclovir with beta-CD-PACM...
  60. pmc Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials
    Deborah Watson-Jones
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    J Clin Microbiol 48:3496-503. 2010
    ..We analyzed specimens from three separate phase III trials of acyclovir (ACV) for prevention of HIV-1 acquisition and transmission to determine if failure of ACV to interrupt HIV ..
  61. ncbi Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient
    G Andrei
    Laboratory of Virology, Rega Institute for Medical Research, K U Leuven, Leuven, Belgium
    Transpl Infect Dis 9:126-31. 2007
    ..stem cell transplant recipient developed a mucosal herpes simplex virus-1 (HSV-1) infection while under acyclovir (ACV) treatment (HSV was later shown to be resistant to ACV)...
  62. ncbi Poly(ethylene-co-vinyl acetate) copolymer matrix for delivery of chlorhexidine and acyclovir drugs for use in the oral environment: effect of drug combination, copolymer composition and coating on the drug release rate
    Padmavathy Tallury
    Center for Oral and Systemic Diseases, Department of Periodontology, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7455, USA
    Dent Mater 23:404-9. 2007
    ..The release rate of an anti-fungal and an anti-microbial drug namely acyclovir (ACY) and chlorhexidine diacetate (CDA) from EVA was investigated individually and as a mixture...
  63. pmc Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir
    L Zeng
    Faculty of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia
    Antimicrob Agents Chemother 53:2918-27. 2009
    b>Acyclovir is effective in the prevention and treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections...
  64. ncbi Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir
    A Verma
    Section of Hematology Oncology, Department of Medicine, University of Illinois at Chicago, 60637, USA
    Bone Marrow Transplant 31:813-6. 2003
    ..All patients received prophylactic ganciclovir from admission until day -2 and prophylactic acyclovir from day -1 until day 180 after transplantation. CMV viremia was treated with ganciclovir...
  65. ncbi Synergistic in vitro interactions between (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1
    Laura B Talarico
    Laboratorio de Virologia, Departamento de Quimica Biologica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina
    Chemotherapy 52:38-42. 2006
    ..Since a late step of virus multiplication is hindered by 6b, we performed studies of drug-drug combination with acyclovir (ACV) and foscarnet (FOS)...
  66. ncbi Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis
    Sonia Burrel
    UPMC Univ Paris 06, ER1 DETIV, F 75013 Paris, France
    J Clin Virol 58:321-4. 2013
    Herpes simplex virus type 1 (HSV-1) is a leading cause of corneal blindness. Acyclovir (ACV) constitutes the standard treatment of HSV infections including herpetic keratitis (HK)...
  67. ncbi Preparation and evaluation of gastroretentive floating tablets of acyclovir
    Rajeev Garg
    Department of Pharmaceutics, ASBASJSM College of Pharmacy, Bela, Ropar 140111, India
    Curr Drug Deliv 6:437-43. 2009
    The present study performed by preparation and evaluation of floating tablets of Acyclovir as model drug for prolongation of gastric residence time...
  68. ncbi Altered mental status from acyclovir
    Gabriel J Martinez-Diaz
    Stanford University School of Medicine, Stanford, California, USA
    J Emerg Med 41:55-8. 2011
    b>Acyclovir is widely used in the treatment of herpes virus infections, particularly herpes simplex virus and varicella-zoster virus...
  69. pmc Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial
    Jairam R Lingappa
    Department of Global Health, Seattle, WA, USA
    Lancet 375:824-33. 2010
    ..Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of acyclovir on HIV-1 progression.
  70. ncbi Dendritic keratitis caused by an acyclovir-resistant herpes simplex virus with frameshift mutation
    Wei Zhang
    Department of Ophthalmology, Ehime University School of Medicine, Shitsukawa, Toon City, Ehime, Japan
    Cornea 26:105-6. 2007
    To report a case of acyclovir-resistant herpes simplex virus (HSV) keratitis after long-term, inconsistent use of topical acyclovir and fluorometholone.
  71. ncbi In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model
    Banmeet S Anand
    Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, Kansas City, Missouri 64110 2499, USA
    Invest Ophthalmol Vis Sci 44:2529-34. 2003
    A dipeptide prodrug of the antiviral nucleoside acyclovir (ACV), val-val-ACV (VVACV), was evaluated in vivo as a potential drug candidate for improving antiviral efficacy against herpetic epithelial and stromal keratitis.
  72. pmc Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase
    Egor P Tchesnokov
    Department of Microbiology and Immunology, McGill University, Montreal, Quebec H3A 2B4, Canada
    J Biol Chem 284:21496-504. 2009
    It has recently been demonstrated that the anti-herpetic drug acyclovir (ACV) also displays antiviral activity against the human immunodeficiency virus type 1 (HIV-1)...
  73. ncbi Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study
    Seok Jin Kim
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Jpn J Clin Oncol 41:353-7. 2011
    b>Acyclovir prophylaxis has been considered as mandatory for patients receiving bortezomib because herpes zoster is a common adverse event associated with the use of bortezomib...
  74. pmc Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis
    M Tod
    Pharmacie and Centre de Recherche en Pathologie Infectieuse et Tropicale, Hopital Avicenne, Bobigny 93009, France
    Antimicrob Agents Chemother 45:150-7. 2001
    b>Acyclovir is approved for the treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections in children by the intravenous and oral routes...
  75. ncbi Erythema multiforme after resolution of herpes zoster by acyclovir
    Ikuko Onishi
    Department of Dermatology, Kyoto Min Iren Central Hospital, 16 1 Nishinokyo Kasuga cho, Nakagyo ku, Kyoto 604 8453, Japan
    Eur J Dermatol 12:370-2. 2002
  76. pmc Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, Washington, USA
    J Infect Dis 203:117-21. 2011
    Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect...
  77. pmc The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women
    Eric Strachan
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98101, United States
    Brain Behav Immun 25:1475-81. 2011
    ..We report results from a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in 19 women for whom personality was assessed at baseline and daily assessments of genital lesions, stress, ..
  78. ncbi Prodrugs of acyclovir--a computational approach
    Rafik Karaman
    Faculty of Pharmacy, Al Quds University, Jerusalem, Palestine
    Chem Biol Drug Des 79:819-34. 2012
    ..molarities values, the predicted t(1/2) (a time needed for 50% of the reactant to be hydrolyzed to products) for acyclovir prodrugs, ProD 1-4, was 29.2 h, 6097 days, 4.6 min, and 8.34 h, respectively...
  79. pmc Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania
    Clare Tanton
    Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, Mortimer Market Centre, off Capper Street, London WC1E 6JB, UK
    Sex Transm Infect 87:406-11. 2011
    ..This study describes HSV shedding patterns among a sample of HSV-2-seropositive women enrolled in a placebo-controlled trial of HSV suppressive therapy (acyclovir 400 mg twice a day) in Tanzania.
  80. ncbi Exacerbation of herpes simplex encephalitis after successful treatment with acyclovir
    Y Ito
    Department of Pediatrics, Nagoya University School of Medicine, Nagoya 466 8550, Japan
    Clin Infect Dis 30:185-7. 2000
    ..27 children with HSE confirmed by polymerase chain reaction (PCR) analysis; all were successfully treated with acyclovir, but 7 (26%) had a relapse of encephalitic illness...
  81. ncbi Monitoring of bystander effect of herpes simplex virus thymidine kinase/acyclovir system using fluorescence resonance energy transfer technique
    Tao Xiong
    College of Life Science, Yangtze University, Jingzhou, Hubei 434025, China
    J Biomed Nanotechnol 8:74-9. 2012
    ..gene therapy mediated by gene transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene followed by acyclovir (ACV) treatment has been reported to inhibit malignant tumor growth in a variety of studies...
  82. ncbi Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection
    M B McKeough
    Department of Medicine, School of Medicine, Room 4B319, University of Utah, 50 North Medical Dr, Salt Lake City, UT 84132, USA
    Arch Dermatol 137:1153-8. 2001
    ..cream [Denavir] and n-docosanol cream [Abreva]) or recently undergone extensive clinical evaluation (acyclovir cream). The relative efficacy of these products is unknown...
  83. pmc Suboptimal management of central nervous system infections in children: a multi-centre retrospective study
    Christine Kelly
    Neurological Infectious Disease, Brain Infections Group, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
    BMC Pediatr 12:145. 2012
    ..We aimed to audit the regional management of central nervous system (CNS) infection in children...
  84. ncbi Importance of C-terminus of herpes simplex virus type 1 thymidine kinase for maintaining thymidine kinase and acyclovir-phosphorylation activities
    Masayuki Saijo
    Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
    J Med Virol 66:388-93. 2002
    We previously isolated an acyclovir (ACV)-resistant herpes simplex virus type 1 (HSV-1), strain TAR, from a child with Wiskott-Aldrich syndrome...
  85. ncbi Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy
    David Lembo
    Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino Ospedale S Luigi Gonzaga, 10043 Orbassano, Torino, Italy
    Int J Pharm 443:262-72. 2013
    ..nanosponges (Carb-NS) carrying carboxylic groups within their structure were purposely designed as novel Acyclovir carriers. TEM measurements revealed their spherical shape and size of about 400 nm...
  86. ncbi Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir
    Denis Marangoni dos Santos
    Departamento de Fisica, UNESP, Sao Jose do Rio Preto, SP, Brazil
    Biochem Biophys Res Commun 308:553-9. 2003
    ..This work reports the first crystallographic study of human PNP complexed with acyclovir (HsPNP:Acy)...
  87. ncbi Stability-indicating polarographic determination of acyclovir through chelation with nickel(II)
    Zeinab A Sheribah
    University of Mansoura, Faculty of Pharmacy, Department of Analytical Chemistry, Mansoura 35516, Egypt
    J AOAC Int 92:419-27. 2009
    A simple and sensitive, stability-indicating polarographic method was developed for the determination of acyclovir (ACV) in raw materials and dosage forms...
  88. ncbi Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus
    Mikiko Suzuki
    Department of Virology, University of Toyama, 2630 Sugitani, Toyama 930 0194, Japan
    Antiviral Res 72:157-61. 2006
    b>Acyclovir and vidarabine both exhibit anti-herpetic activity...
  89. ncbi The potency of acyclovir can be markedly different in different cell types
    G Brand
    Institute of Toxicologic Hygienic and Environmental Science, G Fornaini University of Urbino, Italy
    Life Sci 69:1285-90. 2001
    b>Acyclovir is an acyclic guanine analog with a considerable activity against herpes simplex viruses. We studied the antiherpetic activity of acyclovir in macrophages and fibroblast cell lines...
  90. ncbi Acyclovir skin depot characterization following in vivo iontophoretic delivery
    Srujana Siddoju
    Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA 30341, USA
    Skin Res Technol 17:234-44. 2011
    ..The objective of this study was to investigate the use of iontophoresis for improved topical delivery of acyclovir (ACV) in vivo in hairless rat.
  91. ncbi Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?
    Staffan Eksborg
    Karolinska Pharmacy, Karolinska Hospital, SE 171 76 Stockholm, Sweden
    Med Pediatr Oncol 38:240-6. 2002
    The efficacy of oral acyclovir, a purine nucleoside analogue with activity against human herpes viruses, is limited as a result of its low bioavailability...
  92. ncbi Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir
    Jeanette Hammer Andersen
    Department of Medical Microbiology, University Hospital of North Norway, N 9038, Tromsø, Norway
    Antiviral Res 58:209-15. 2003
    ..concentrations (EC(50)) for LF and Lfcin against several clinical isolates of HSV-1 and HSV-2, including acyclovir (ACV)-resistant strains, were determined...
  93. ncbi Spectrophotometric determination of acyclovir and ribavirin in their dosage forms
    Mohie Khaled Sharaf El-Din
    University of Mansoura, Faculty of Pharmacy, Department of Analytical Chemistry, Mansoura, 35516, Egypt
    J AOAC Int 89:631-41. 2006
    ..and reliable spectrophotometric methods have been developed for the determination of 2 antiviral drugs, acyclovir (ACV) and ribavirin (RBV), in their pharmaceutical formulations...
  94. pmc CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections
    Mark N Prichard
    University of Alabama at Birmingham, Department of Pediatrics, 128 Children s Harbor Building, 1600 6th Avenue South, Birmingham, AL 35233 1711, USA
    Antimicrob Agents Chemother 55:4728-34. 2011
    Although acyclovir (ACV) has proven to be of value in the therapy of certain herpes simplex virus (HSV) infections, there is a need for more effective therapies, particularly for serious infections in neonates and immunocompromised ..
  95. pmc Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman
    Todd Czartoski
    Molecular Virology Laboratory, University of Washington, 960 Republican St, Seattle, WA 98195, USA
    J Clin Microbiol 44:1584-6. 2006
    ..After she initially responded to intravenous acyclovir, she was switched to oral valacyclovir. She developed respiratory failure and opportunistic infections and died...
  96. ncbi Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome
    Roger Wong
    Guy s and St Thomas Hospital NHS Foundation Trust, London, UK
    Ophthalmology 117:556-60. 2010
    ..To study the effects of intravitreal foscarnet and the clinical differences between varicella zoster virus (VZV) and herpes simplex virus (HSV) induced acute retinal necrosis (ARN)...
  97. ncbi Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis
    Rui Duan
    Department of Virology, Erasmus Medical Centre, Rotterdam, The Netherlands
    J Infect Dis 200:1402-14. 2009
    The incidence and clinical significance of herpes simplex virus type 1 (HSV-1) acyclovir resistance were determined in patients with recurrent herpetic keratitis (RHK).
  98. pmc Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir
    Jwala Jwala
    Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA
    J Ocul Pharmacol Ther 27:163-72. 2011
    ..was to develop and characterize polymeric nanoparticles of appropriate stereoisomeric dipeptide prodrugs of acyclovir (L-valine-L-valine-ACV, L-valine-D-valine-ACV, D-valine-L-valine-ACV, and D-valine-D-valine-ACV) for the ..
  99. ncbi The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa
    Peter Vickerman
    Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom
    Sex Transm Dis 38:401-9. 2011
    ..The cost-effectiveness of daily aciclovir for delaying HIV-1 disease progression in women not eligible for antiretroviral therapy (ART) is estimated...
  100. ncbi Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers
    E G de Jalón
    Centro Galenico, Departamento de Farmacia y Tecnologia Farmaceutica, Universidad de Navarra, 31080 Pamplona, Spain
    J Control Release 75:191-7. 2001
    The goal of this work was to increase the amount of acyclovir (ACV) in the basal epidermis, site of Herpes virus simplex infections, using microparticles as carriers...
  101. ncbi Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis
    J Poissy
    Service Universitaire des Maladies Infectieuses et du Voyageur, Tourcoing, France
    Clin Microbiol Infect 15:560-4. 2009
    ..in herpes simplex virus (HSV) encephalitis (HSE) is the delay between hospital admission and initiation of acyclovir. In this study, factors associated with late initiation of acyclovir were identified...

Research Grants63

  1. N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti
    Aquilur Rahman; Fiscal Year: 2010
    ..N-MCT is active against all dsDNA viruses, except CMV, including acyclovir (ACV)-resistant HSV-1 and cidofovir (CDV)-resistant cowpox viruses, and has not been tested as yet against HPV...
  2. N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti
    Aquilur Rahman; Fiscal Year: 2013
    ..include: 1) Cytotoxicity only in HSV-infected cells 2) HSV-tk dependant antiviral activity 3) Activity against acyclovir (ACV)-resistant HSV 4) Activity against HSV-1, HSV-2, HSV-8, vaccinia and cowpox viruses 5) Greater potency than ..
  3. Mechanisms of IVIG Protection in Viral Encephalitis
    EDOUARD M CANTIN; Fiscal Year: 2010
    ..fatal HSE in 129 mice results from hyper-inflammatory responses involving macrophages and neutrophils and that acyclovir which inhibits HSV replication is largely ineffective in protection against HSE...
  4. Genetic analysis of Herpes virus neurotropism and encephalitis
    JENNIFER HART LAVAIL; Fiscal Year: 2011
    ..HSV can become latent in infected neurons and can become resistant to treatment with acyclovir and acyclovir-derived drugs...
  5. A novel peptide therapy for treatment of herpetic stromal keratitis
    Partha S Bhattacharjee; Fiscal Year: 2010
    ..The therapeutic efficacy of the anti-viral peptide will also be tested in vivo against acyclovir-resistant HSV-1 (to demonstrate that this antiviral mechanism of action is different than the nucleoside ..
  6. Targeting the DNA Damage Response for the Treatment of Herpes Simplex Labialis
    WILLIAM DONEGAN; Fiscal Year: 2013
    ..9% in recipients of hematopoietic stem cells. Since most of the drugs used to treat infection are derived from acyclovir and have the same mechanism of action, there are no safe and effective drugs available to treat these ..
  7. ASSEMBLY OF THE HERPES SIMPLEX VIRUS CAPSID
    Jay C Brown; Fiscal Year: 2012
    ..to be the cause of widespread human illness despite the availability of a reasonably effective therapeutic, acyclovir and related compounds...
  8. Identification and evaluation of novel therapeutic targets for virus-induced neur
    Kenneth L Tyler; Fiscal Year: 2013
    ..Proven treatments for viral encephalitis are limited to only a few viruses and even when treatments exist (e.g. acyclovir for herpes simplex encephalitis) disability and death remain significant...
  9. Mendelian genetic predisposition to herpes simplex encephalitis in childhood
    Jean Laurent Casanova; Fiscal Year: 2013
    ..HSE is the most common sporadic viral encephalitis in Western countries and acyclovir-treated survivors often suffer from severe neurological sequels...
  10. Mechanisms of Apoptosis in Virus-Infected Neurons
    JOHN DAVID BECKHAM; Fiscal Year: 2012
    ..While acyclovir therapy is effective for herpes simplex encephalitis, morbidity and mortality are still prominent in infected ..
  11. REPRESSION AND ACTIVATION OF PERSISTING HSV GENOMES
    Neal A DeLuca; Fiscal Year: 2013
    ..Nucleoside analogues, such as acyclovir and its derivatives, target viral DNA replication...
  12. Herpes Simplex Virus Therapy for the Treatment of Neointimal Hyperplasia
    CHRISTOPHER LOWTHER SKELLY; Fiscal Year: 2012
    ..at least 4 weeks;exhibits no systemic toxicity;can be eliminated at will by administration of the antiviral drug acyclovir;and significantly reduces VSMC proliferation and restenosis in vein grafts...
  13. Impact of HSV-2 on Female Genital Tract Mucosal Immunity &HIV Infection
    Betsy C Herold; Fiscal Year: 2013
    ..Oral suppressive acyclovir failed to reduce the risk of HIV acquisition or prevent transmission of HIV from HIV/HSV-2 co-infected ..
  14. Mechanism of Neurotrophin Latency Response in a HSV1 Vestibular Neuritis Model
    PAMELA CAROL ROEHM; Fiscal Year: 2013
    ..the US11 protein, we have infected dissociated VGNs harvested from postnatal rats, prevented this infection with acyclovir, and established a quiescent viral infection...
  15. Cellular genes and signaling pathways as therapeutic targets for virus-induced CN
    Kenneth L Tyler; Fiscal Year: 2013
    ..Proven treatments for viral encephalitis are limited to only a few viruses and even when treatments exist (e.g. acyclovir for herpes simplex encephalitis) disability and death remain significant...
  16. Seminal HIV-1 Shedding and Drug Resistance in HIV-1/HSV-2 Coinfected Men on HAART
    Deborah Anderson; Fiscal Year: 2009
    ..Clinical trials are currently underway to determine whether suppression of HSV-2 infection with acyclovir impacts HIV-1 acquisition and transmission rates...
  17. Alpha-herpevirus assembly egress and viral particle heterogeneity
    Gregory Allan Smith; Fiscal Year: 2013
    ..Despite the availability of the antiviral compound acyclovir, several severe forms of disease caused by these viruses remain prevalent in this country and worldwide...
  18. Alpha-herpesvirus assembly, egress and viral particle heterogeneity
    Gregory Smith; Fiscal Year: 2009
    ..Despite the availability of the antiviral compound acyclovir, several severe forms of disease caused by these viruses remain prevalent in this country and world wide...
  19. Bioresponsive Combination Microbicide Delivery System for HIV and HSV
    PATRICK FRANKLIN contact KISER; Fiscal Year: 2010
    ..The gels will be loaded with the antiviral nucleoside inhibitors Tenofovir (TNFV) and Acyclovir (ACV), and a viral neutralizing agent CAP (cellulose acetate phthalate)...
  20. Mechanisms of apoptosis in the central nervous system
    Kenneth Tyler; Fiscal Year: 2009
    ..Similarly, although treatment with acyclovir improves the outcome of herpes simplex type-1 (HSV-1) encephalitis, the most common acute sporadic encephalitis ..
  21. Dissecting HSV-2 immunity using cell-targeted siRNAs
    Deborah Palliser; Fiscal Year: 2012
    ..Up to 90 percent of people with HIV-1 are infected with HSV-2, and treatment with acyclovir reduces HIV-1 genital secretions, and thereby HIV-1 transmission...
  22. 1,2,3-Triazole nucleobases in antiviral nucleoside analogues
    ERLAND P STEVENS; Fiscal Year: 2010
    ..Specifically targeted sugars include those found in acyclovir, penciclovir, and abacavir...
  23. Combination Therapy using an Innovative Bioadhesive Polymeric Transmucosal Delive
    GITA SHANKAR; Fiscal Year: 2013
    ..this novel formulation both alone, for its inherent microbicidal properties;and formulate it with tenofovir and acyclovir, to demonstrate a safe and effective proof-of-principle product for the control of HIV-1 infections that, in ..
  24. MODULATION OF ONCOGENIC AGENTS BY MARIJUANA
    PETER GABOR MEDVECZKY; Fiscal Year: 2010
    ..THC inhibits these gamma herpesviruses in micromolar concentrations comparable with known antiviral drugs acyclovir and ganciclovir...
  25. Interaction between HSV-2 and the vaginal microbiome in the female genital tract
    CHRISTINE MICHELLE JOHNSTON; Fiscal Year: 2012
    ..In a subset of women, we will determine whether suppression of HSV-2 shedding using acyclovir will result in improved vaginal flora as measured by a decrease in Nugent score...
  26. Herpes Simples Virus Capsid Assembly and DNA Packaging
    FREDERICK L HOMA; Fiscal Year: 2011
    ..While some herpesvirus infections can be treated with acyclovir and similar nucleoside analogues substantial unmet medical needs remain for most herpesvirus diseases...
  27. Mucus-penetrating nanoparticles for sustained microbicide delivery
    Justin Hanes; Fiscal Year: 2009
    ..In the R21 phase we propose to develop acyclovir-loaded MPP to evaluate in our mouse HSV models for efficacy, duration, vaginal distribution, and toxicity...
  28. Bell's Palsy-Randomized Clinical Trial
    John Neely; Fiscal Year: 2007
    ..to the use of anti-inflammatories, principally oral prednisone, in combination with an oral antiviral, such as acyclovir or its pro-drug, valacyclovir...
  29. Bioequivalence of topical drug products: in vitro - in vivo correlations
    Audra L Stinchcomb; Fiscal Year: 2013
    ..A systematic examination of several key classes of topical drug products will be undertaken including, but not limited to lidocaine, triamcinolone acetonide, tretinoin, acyclovir and metronidazole.
  30. Antagonizing miRNAs in a strategy to cure HSV latency
    Donald M Coen; Fiscal Year: 2013
    ..that help maintain latency;and 3) Irreversibly inactivate the resultin replicating HSV using the anti-HSV drug acyclovir. The R21 phase of this project is a collaborative effort of three labs...
  31. NOVEL METHODOLOGIES AND IVIVC APPROACHES TO ASSESS BIOEQUIVALENCE OF TOPICAL DRUG
    Frank Sinner; Fiscal Year: 2013
    ..to establish BE, starting with the only FDA- accepted in vitro approach as per the "FDA Draft Guidance on Acyclovir". We will then investigate innovative in vitro systems based on dOFM as a new in vitro approach for BE...
  32. Electroporation and transcutaneous extraction of drugs
    SATHYANARAYANA MURTHY; Fiscal Year: 2006
    ..this application emanates from our recent success in utilizing ETE for sampling of drugs such as salicylic acid, acyclovir, ibuprofen, fluconazole and cefpodoxime from the dermal ECF...
  33. AZIDE TECHNOLOGY FOR DRUG DEVELOPMENT
    Kyoichi Watanabe; Fiscal Year: 2001
    ..Phase I, we will synthesize three new 6-azidopurine derivatives as prodrugs of clinically used antiviral agents, Acyclovir, ganciclovir and penciclovir, and three novel nucleosides containing the azide group at the 6 position of the ..
  34. Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis
    Thomas J Smith; Fiscal Year: 2013
    ..The original aim of this proposal was to develop IVRs to release acyclovir, since genital herpes co-infection significantly increases the rate of HIV transmission...
  35. Intravaginal Ring Delivery of Safe &Effective Microbicides to Prevent HIV &HSV
    Betsy C Herold; Fiscal Year: 2012
    ..We will address the importance of the biological synergy between HIV and HSV by also combining acyclovir with ARV drugs to provide local sustained suppression of HSV...
  36. Intra-oral Drug Delivery Systems for HIV/AIDS Patients
    Steven Offenbacher; Fiscal Year: 2007
    ..for sustained release of current FDA approved therapeutic agents, chlorhexidine, nystatin, ganciclovir and acyclovir, alone or in combination...
  37. ANTIVIRAL THERAPY WITH N-DOCOSANOL PLUS ACYCLOVIR
    LAURA POPE; Fiscal Year: 2000
    ..The guanosine analog acyclovir remains a leading approved drug for the treatment of oral and genital HSV diseases...
  38. ASSEMBLY OF THE HERPES SIMPLEX VIRUS CAPSID
    Jay Brown; Fiscal Year: 2007
    ..to be the cause of widespread human illness despite the availabiltiy of a reasonably effective therapeutic, acyclovir, and related compounds...
  39. Delivery of Agents by Modulating Junctions with Zot
    Natalie Eddington; Fiscal Year: 2006
    ..in the brain and data has shown that Zot enhances the BBB delivery of therapeutic agents (doxorubicin, inulin, acyclovir). SA5...
  40. Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents
    Terry L Bowlin; Fiscal Year: 2010
    ..The first generation of MP compounds were biosteric analogs of acyclovir with the C-O-C moiety replaced by the methylenecyclopropane moiety...
  41. MOUSE THYMIC VIRUS (MTLV)
    Stephen Morse; Fiscal Year: 1991
    ..Effect of antiviral agents (Acyclovir, Ganciclovir, and others) will be defined for MTLV and compared with known data on HHV-6.
  42. GOSSYPOL DERIVATIVES AS COVALENT CARRIERS OF ANTIVIRALS
    Robert Royer; Fiscal Year: 1991
    ..human immunodeficiency virus (HIV) and herpes simplex virus (HSV), such as aziodothymidine, ribavirin and acyclovir, and to test these conjugated derivatives for activity in vitro...
  43. Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission
    KAREN MARK; Fiscal Year: 2009
    ..We plan to conduct an open-label randomized clinical trial of daily suppressive acyclovir versus episodic acyclovir for treatment of genital herpes recurrences among HSV-2 seropositive heterosexual men ..
  44. HIV Pathogenesis, prevention and treatment in the Andes
    Jorge Sanchez; Fiscal Year: 2006
    ..and HSV co-infected men and women, and will assess the reduction in genital HIV shedding with daily suppressive acyclovir; Project 2 will test immunologic and virologic outcomes, adherence, and rate of emergence of ARV resistance with ..
  45. CONVENTIONAL DRUGS & ANTIVIRAL OLIGONUCLEOTIDES FOR HBV
    John Newbold; Fiscal Year: 1990
    ..1. Inhibitors of the hepadnavirus reverse transcriptase/DNA polymerase. Such compounds (e.g., acyclovir) are already being implemented in treatment protocols for chronic HBV infection; others, like azidothymidine are ..
  46. Substrate requirements of the bile acid transporter
    JAMES POLLI; Fiscal Year: 2009
    ..b>Acyclovir's bioavailability was doubled in rats using a prodrug that targets hASBT...
  47. BORONIC ACID ANALOGS OF NUCLEOSIDE-5'-PHOSPHATES
    BERNARD SPIELVOGEL; Fiscal Year: 1993
    ..The Phase I effort will mainly concentrate on the synthesis of an analog of acyclovir monophosphate and to develop methods that may be utilized for the synthesis of analogs of other nucleoside ..
  48. CONTROL OF HIV-1 AND HSV-1 INFECTION WITH PLANT LIGNANS
    RU CHIH HUANG; Fiscal Year: 2000
    ..Initial treatments with anti viral agents (such as acyclovir for HSV and reverse transcriptase and viral protease inhibitors for HIV-1) have been found to be quite effective...
  49. Liver-Targeted Prodrugs for the Treatment of Hepatitis B
    PAUL VAN POELJE; Fiscal Year: 2001
    The synthesis and characterization of novel prodrugs of the antiviral nucleosides acyclovir, penciclovir, and lamivudine are proposed with the purpose of identifying an agent with improved efficacy in the treatment of hepatitis B...
  50. PF-8 AND POL-8 OF KSHV AS TARGETS OF VIRAL DNA SYNTHESIS
    Robert Ricciardi; Fiscal Year: 2001
    ..Since standard herpesvirus drug treatments (e.g.., acyclovir) are not effective against KSHV, there is heightened interest in developing new KSHV antivirals...
  51. Cell Tracking and imaging gene expression in the brain
    Harish Poptani; Fiscal Year: 2006
    ..are suitable only for superficial organs while herpes-simplex virus-thymidine kinase gone requires binding to acyclovir ligands that do not cross the blood brain barrier...
  52. HERPES EYE DISEASE
    Roy Beck; Fiscal Year: 2000
    ..Two studies will be randomized comparisons of acyclovir vs...
  53. Cdk inhibitors: novel antivirals for VZV
    Jennifer Moffat; Fiscal Year: 2007
    ..Current treatments with acyclovir and its derivatives have met with some success, but pain and other sequelae often persist despite therapy...
  54. TARGETED GENE THERAPIES FOR AIDS
    Leaf Huang; Fiscal Year: 1992
    ..cells would then make the cells sensitive to drugs which are specific substrates for HSVTK, such as DHPG and acyclovir. The cellular and viral DNA syntheses of the infected cells would be inhibited by these drugs...
  55. NOVEL INHIBITORS OF THE HCMV SERINE PROTEASE
    Dennis Liotta; Fiscal Year: 1999
    ..Although drugs against HCMV are available, including ganciclovir and acyclovir, they are nucleotide analogs and have serious side effects...
  56. NEW TOPICAL PROPHYLACTIC AGENT FOR GENITAL HERPES
    David Gershon; Fiscal Year: 2000
    ..Yearly worldwide sales of the leading antiherpetic drug, acyclovir, exceed $1 billion...
  57. Sustained release acyclovir for prophylaxis of genital herpes
    Thomas Smith; Fiscal Year: 2009
    ..We propose to utilize this platform to develop sustained release vaginal ring formulations for acyclovir. We have formulated prototype rings that release acyclovir in a linear fashion over 30 days...
  58. ENHANCED DELIVERY OF ALPHA INTERFERON FOR GENTIAL HERPES
    Peter Kelleher; Fiscal Year: 2000
    ..In addition oral acyclovir does not reduce the symptoms of recurrent infections and the effects of long term use are unknown...
  59. MINORITY PREDOCTORAL FELLOWSHIP PROGRAM
    Elizabeth Hunsperger; Fiscal Year: 2001
    ..Although treatment with acyclovir can attenuate the productive infection, there is no known treatment for latently infected neurons...
  60. PRE-CLINICAL DEVELOPMENT OF NOVEL HSV-2 ANTIGENS.
    Nancy Hosken; Fiscal Year: 2000
    ..has increased substantially in the past two decades, despite the availability of anti-viral drugs, such as acyclovir, to treat the disease...
  61. HEDS CLINIC
    ROBERT HYNDIUK; Fiscal Year: 1991
    ..The primary goal of the HEDS is to determine clinical guidelines for the rational use of oral acyclovir (ACV) in herpetic eye infections utilizing a set of clinical trials conducted at major centers in ocular ..
  62. EBV PATHOGENESIS IN HIV-ASSOCIATED HAIRY LEUKOPLAKIA
    DENNIS WALLING; Fiscal Year: 2003
    ..The results of this study will elucidate molecular mechanisms of EBV pathogenesis in HLP applicable to other EBV-associated diseases, including nasopharyngeal carcinoma and HIV-associated lymphomas. ..
  63. Novel inhibitors of the replication of poxviruses
    Johan Neyts; Fiscal Year: 2004
    ..The final goal of this application is to advance a compound for the treatment of (systemic or cutaneous) poxvirus infections to the initial stages of development, i.e., selecting an IND candidate. ..